知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.015 秒)

    NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR
    4.
    发明申请
    NOVEL THROMBOLYTIC MOLECULES AND A PROCESS THEREFOR 有权
    新型血小板分子及其过程

    公开(公告)号：US20100015123A1

    公开(公告)日：2010-01-21

    申请号：US12300150

    申请日：2007-05-11

    申请人： Krishna Murthy Ella ,  Kandaswamy Sumathy

    发明人： Krishna Murthy Ella ,  Kandaswamy Sumathy

    IPC分类号： A61K38/48 ,  C12N9/72 ,  C12N9/70 ,  C12P19/34 ,  C12N15/00 ,  C12P21/02

    CPC分类号： C07K14/31 ,  C07K2319/035

    摘要： New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.

    摘要翻译： 新的血栓溶解蛋白分子例如重组葡激酶或链激酶，尿激酶，组织纤溶酶原激活剂等及其合适的变体，用于通过融合或通过合成候选溶栓分子与脑组织或任何其他组织靶向， 包含含有蛋白质转导结构域的强两亲性α螺旋的蛋白质序列。 用蛋白质转导结构域进行工程化的溶血蛋白分子可用于增强这些蛋白质溶解分子在细胞膜和组织（包括血脑屏障）中的摄取，并用于治疗血管性血栓形成，包括脑血管障碍 由脑血栓形成或脑出血引起的，当用作治疗剂时。 克隆，表达，纯化和蛋白质转导这些蛋白质跨细胞膜的设计和过程。

    Eukaryotic Based Synergistic Formulation for Gastro-Intestinal Disorders
    6.
    发明申请
    Eukaryotic Based Synergistic Formulation for Gastro-Intestinal Disorders 审中-公开
    用于肠胃功能障碍的真核基因协同配方

    公开(公告)号：US20080226614A1

    公开(公告)日：2008-09-18

    申请号：US11660976

    申请日：2004-08-23

    申请人： Krishna Murthy Ella ,  Srinivas Kannappa Vellimedu ,  Sivasankara Rao Sunkara

    发明人： Krishna Murthy Ella ,  Srinivas Kannappa Vellimedu ,  Sivasankara Rao Sunkara

    IPC分类号： A61K45/00 ,  A61K36/06

    CPC分类号： A61K36/064 ,  A61K9/0095 ,  A61K9/2081 ,  A61K35/747 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention describes a eukaryotic based synergistic formulation for gastro-intestinal disorders comprising eukaryolics and adjuncts selected from pharmaceutically and or physiologically acceptable components. The invention also describes the manner in which the eukaryolics are isolated from tropical fruits , The medium used for growing them and the method used to convert the formulation to dispensable forms. The medium comprising Glucose for carbon source, soybean casein dextrose medium (SCDM) for Nitrogen source, MgSo4, KCl, NaCl, (NH)4HPO4 and with microelements like MnSO4, FeSO4, Boric acid and Vitamins, D-Biotin and thiamine HCl ranging from 0.001% to 0.6% and designated as BBIL-SB. The formulation can be effectively used to prevent and or cure gastro intestinal disorders by administering in various forms to the mammals including human suffering there from, in a required quantity.

    摘要翻译： 本发明描述了一种用于胃肠疾病的基于真核的协同制剂，其包括选自药学和/或生理上可接受的组分的真核细胞和辅助剂。 本发明还描述了从热带水果中分离真核细胞的方式。用于培养它们的培养基和用于将制剂转化成可分配形式的方法。 包含用于碳源的葡萄糖，用于氮源的大豆酪蛋白葡萄糖培养基（SCDM），MgSo 4，KCl，NaCl，（NH）4HPO 4以及诸如MnSO 4，FeSO 4，硼酸和维生素，D-生物素和硫胺素的微量元素的培养基，其范围从 0.001％至0.6％，称为BBIL-SB。 该制剂可以有效地用于预防和/或治疗胃肠道疾病，其通过以所需数量向哺乳动物施用各种形式，包括患有这些哺乳动物。

    STABLE IMMUNOGENIC PROTEIN HAVING MULTIPLE CYSTEINES MOLECULES PROCESS THEREFOR AND COMPOSITION THEREOF
    7.
    发明申请
    STABLE IMMUNOGENIC PROTEIN HAVING MULTIPLE CYSTEINES MOLECULES PROCESS THEREFOR AND COMPOSITION THEREOF 审中-公开
    具有多种CYSTEINES分子的稳定的免疫原性蛋白及其组合物

    公开(公告)号：US20120269856A1

    公开(公告)日：2012-10-25

    申请号：US13376660

    申请日：2009-07-23

    申请人： Krishna Murthy Ella ,  Ganapathy Ravi

    发明人： Krishna Murthy Ella ,  Ganapathy Ravi

    IPC分类号： A61K39/015 ,  A61P37/04 ,  A61P33/06 ,  C12P21/00 ,  C07K14/00

    CPC分类号： C07K14/445 ,  A61K39/015 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  Y02A50/412

    摘要： The invention describes a stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98% particularly rPvRII and/or rPfF2. It also discloses a method for producing said immunogenic protein comprising the following steps: culturing the host E. coli cells containing a desired recombinant gene construct comprising a codon optimized gene sequence of rPvRII and/or rPfF2 to produce cells in high density; inducing expression rPvRII and/or rPfF2 as inclusion bodies; harvesting the cells and isolating the said inclusion bodies; separating rPvRII and/or rPfF2 from inclusion bodies by repeated sequential washing and solubilizing with chaotrophic agents comprising guanidine hydrochloride and/or urea; purifying the protein by subjecting to metal-chelate affinity chromatography; re-folding of the purified rPvRII and/or rPfF2 obtained in step e) with a redox system to recover a high yield of the soluble protein, followed by further purifying the desired protein by removing impurities by subjecting to chromatography. Further the invention discloses formulation comprising rPvRII or rPfF2, preferably being lyophilized using polysaccharides preferably sucrose, lactose, and pharmaceutically acceptable adjuvants such as aluminum hydroxide, aluminum phosphate, CpG nucleotides, non-CpG nucleotides, Montanide ISA-720, MF-59, Mono-phosphoryl Lipid-A (MPL-A) and QS-21.

    摘要翻译： 本发明描述了具有多个半胱氨酸分子的稳定的免疫原性蛋白质，其中蛋白质具有至多两年的稳定性，纯度大于98％，特别是rPvRII和/或rPfF2。 本发明还公开了一种生产所述免疫原性蛋白的方法，包括以下步骤：培养含有包含rPvRII和/或rPfF2的密码子优化的基因序列的所需重组基因构建体的宿主大肠杆菌细胞以高密度产生细胞; 诱导表达rPvRII和/或rPfF2作为包涵体; 收集细胞并分离所述包涵体; 通过重复顺序洗涤和与包含盐酸胍和/或尿素的混合营养剂溶解来分离rPvRII和/或rPfF2从包涵体中分离; 通过金属螯合亲和层析纯化蛋白质; 用氧化还原系统将步骤e）中获得的纯化rPvRII和/或rPfF2重新折叠，以回收高产量的可溶性蛋白质，随后通过色谱除去杂质进一步纯化所需蛋白质。 此外，本发明公开了包含rPvRII或rPfF2的制剂，优选使用多糖优选蔗糖，乳糖和药学上可接受的辅剂如氢氧化铝，磷酸铝，CpG核苷酸，非CpG核苷酸，Montanide ISA-720，MF-59，Mono - 磷脂脂酸（MPL-A）和QS-21。

    Chimeric fusion proteins
    10.
    发明授权
    Chimeric fusion proteins 有权
    嵌合融合蛋白

    公开(公告)号：US08968728B2

    公开(公告)日：2015-03-03

    申请号：US12300150

    申请日：2007-05-11

    申请人： Krishna Murthy Ella ,  Kandaswamy Sumathy

    发明人： Krishna Murthy Ella ,  Kandaswamy Sumathy

    IPC分类号： A61K38/48 ,  C12N9/72 ,  C12N9/70 ,  C12P21/04 ,  C07H21/04 ,  C07K1/00 ,  C07K14/31

    CPC分类号： C07K14/31 ,  C07K2319/035

    摘要： New thrombolytic protein molecules such as recombinant staphylokinase or streptokinase, urokinase, tissue plasminogen activator and the like, and suitable variants thereof, for targeting to brain tissue or any other tissue by either fusing to, or by synthesizing the candidate thrombolytic molecule(s) with a protein sequence comprising a strong amphipathic alpha helix containing protein transduction domain. Thrombolytic protein molecule(s) so engineered with the protein transduction domain is useful for enhanced uptake of such protein thrombolytic molecule(s) across the cell membranes and tissues including the blood brain barrier and find their use in the treatment of vascular thrombosis including cerebrovascular disorders caused by cerebral thrombosis or cerebral haemorrhage when used a as a therapeutic. The design and processes for cloning, expression, purification and protein transduction of such proteins across cell membranes.

    摘要翻译： 新的血栓溶解蛋白分子例如重组葡激酶或链激酶，尿激酶，组织纤溶酶原激活剂等及其合适的变体，用于通过融合或通过合成候选溶栓分子与脑组织或任何其他组织靶向， 包含含有蛋白质转导结构域的强两亲性α螺旋的蛋白质序列。 用蛋白质转导结构域进行工程化的溶血蛋白分子可用于增强这些蛋白质溶解分子在细胞膜和组织（包括血脑屏障）中的摄取，并用于治疗血管性血栓形成，包括脑血管障碍 由脑血栓形成或脑出血引起的，当用作治疗剂时。 克隆，表达，纯化和蛋白质转导这些蛋白质跨细胞膜的设计和过程。